Abstract.: This paper reviews the public and scientific debates over the risks and benefits of aquaculture and aquatic biotechnology worldwide, and in the United States in particular. The basic argument is that business tends to respond to uncertainty with innovation in management and technology. Technological evolution in the fish business is therefore interpreted as a continuous response to new environmental and socioeconomic uncertainties and subsequent regulation. The use of aquatic biotechnology in fish breeding is just the latest technological response, but also the most controversial. Growth-enhanced transgenic salmon may become the first bioengineered animal product approved for use as food in the United States. The fish may boost future salmon harvests, contribute to productivity increases in aquaculture and lower consumer prices for salmon. But it also faces public opposition, reluctant investors and scientific skepticism due to mainly environmental concerns. The paper argues that even though the regulatory framework in the United States is well-elaborated, it may not be able to reassure public opposition once transgenic salmon should be approved as a ‘new animal drug'. Analogous to genetically modified food crops, the consumer market rather than regulation will determine the ultimate fate of transgenic fis
